Sunlenca approved for treatment-resistant populations, but a number of other drugs will cease production, some of which are included in PEP guidelines.
Sunlenca approved for treatment-resistant populations, but a number of other drugs will cease production, some of which are included in PEP guidelines.
Tobacco use as a complicating factor in workplace injury and recovery.
Exposure to various gases and vapors has been associated with autoimmune disease
Two new studies highlight marijuana’s analgesic effects.
The FDA may receive a new drug application as early Q3 of 2023.
Preliminary findings from Healthe’s 2023 industry survey.
Tzield (teplizumab-mzwv) injections can delay onset by several months or years.
How the timing and accuracy of diagnostic testing can determine the course of a claim.
This vaccine blocks fentanyl from entering the brain and triggering euphoric effect.
This report contains a high level report on the status of the Texas workers’ comp system.
Risk & Insurance® magazine taps Healthe’s VP of Clinical Services for considerations on retaining a healthy and happy workforce.
First-time generics are available for drugs that treat COPD, HIV, hypertension, and more.
The insurance sector continues to face IT talent shortages – how does this impact workers’ comp organizations?
An update to the 2016 guidelines has been issued, promoting greater flexibility for individualized patient-centered care.
Maryland and Missouri voters pass recreational legalization.
Data insights on medical payments for 18 state workers’ comp systems.
A series of reports from NCCI examine how medical costs and workforce demographics are changing.
The potential for low amniotic fluid can cause significant health issues.
Smaller, more niche drug trends across different populations and geographies
The National Safety Council provides information on mental health, workplace safety, and more.
The only pre-exposure prophylactic for COVID-19 may not provide protection for certain variants.
Healthe’s Chief Information Officer, Brett Luna, speaks to Risk & Insurance® Magazine about this trending topic.
This antidepressant can yield results as soon as one week, which could generate popularity.
Gaining visibility into Social Determinants of Health that intersect with workplace injury and recovery.
A new report from the WCRI addressed psychosocial barriers to recovery and intervention strategies.
Moderna and Pfizer boosters have been updated to target the omicron variant.
Stop by our educational session or visit our booth to take part in our industry survey.
Novavax COVID-19 Vaccine, Adjuvanted will require two doses given three weeks apart.
How different forms of violence can be detrimental to worker performance and recovery.
A systematic review from the Annals of Internal Medicine evaluates different cannabis formulations.
If enacted, this bill would create an exemption where gig workers do not receive employee benefits.
Stephanie Arkelian dives into the issue with Risk & Insurance® magazine, and an upcoming presentation at the Georgia Board of Workers’ Compensation Annual Educational Conference.
A mix-up between 30 mg and 60 mg tablets could cause severe adverse events.
With greater legalization and public approval, the question of safety grows more important.
A WCRI report explores telemedicine utilization.
WCRI explores how drug payments varied across 28 states for key drug therapy groups.
AZD1236, currently in Phase 2 trials, has shown an 80% preservation in nerve function following spinal cord injury.
Silvia Sacalis and Tate Rice take turns in WorkCompWire’s Leaders Speak Series.
Artri Ajo King contains undeclared diclofenac, creating safety concerns.
Ancillary medical product and service shortages and how to manage them.
A new report from the CDC found that 10% of overdose deaths in 2019-2020 involved gabapentin.
A total of 19 states now allow for recreational marijuana in adults aged 21 and older.
Risk and Insurance® magazine speaks to industry professionals, including Healthe’s Director of Product Management, Tate Rice.
Undeclared muscle relaxants and anti-inflammatory drugs could interact with a patient’s care.
Millions of workers are changing occupations, leading to ripple effects for comp.
Spending and utilization are returning to pre-pandemic levels, with biologics growing in prominence.
The public comment period is underway for this action, which could help with safer drug disposal.
Healthe’s VP of Clinical Services will join a discussion on post-COVID lessons for workers’ comp.
VX-548 delivered significant improvements in pain with few adverse events.
Women workers were more adversely impacted by the pandemic and the recession.
Quest Diagnostics reports increased positivity rates for marijuana in employee drug screenings.
Adults aged 50 and older and immunocompromised individuals may receive a second booster dose.
Carriers share their thoughts on successful RTW programs.
A new muscle relaxant for the treatment of spasticity, including from spinal cord injuries.
Nearly 500 stakeholders share their thoughts on industry challenges and priorities.
Proposed changes are open to public comment until April 11th.
After a drop in activity due to the pandemic, five states are now considering legislation.
Healthe’s VP of Industry and State Affairs, Sandy Shtab, joined an educational webinar from IAIABC.
Buprenorphine is an opioid used to treat pain, as well as opioid-use disorder.
Legislation could potentially reclassify gig workers as employees entitled to workers’ comp.
